Fair value (multi-method)
Four independent methods triangulate what REGN is worth. The headline is the Forward-DCF intrinsic value at a normalized growth rate; the margin of safety compares it to the current price.
Estimated fair value (Forward DCF)
$1,734.42
Method range
$218.03 – $1,734.42
median $797.47
Valuation methods
Each method’s implied fair value per share and its upside versus the current price. Missing methods (no analyst coverage, negative earnings, etc.) are shown as “—”.
| Method | Fair value | Upside vs price |
|---|---|---|
| Forward DCF | $1,734.42 | +166.35% |
| Exit multiple | $771.56 | +18.49% |
| Analyst target | $823.39 | +26.45% |
| Graham number | $218.03 | -66.52% |
- Forward DCF$1,734.42
- Exit multiple$771.56
- Analyst target$823.39
- Graham number$218.03
Stock price
$651.18
FCF / share (TTM)
$8.16
3Y FCF CAGR
-10.4%
Fair value @ hist. growth
$83.90
This analysis is for informational purposes only and is not financial advice. Scenario prices and DCF-style figures depend on your assumptions and data from public filings and estimates. They are not forecasts of future returns.
Implied FCF growth
14.0%
per year over your projection horizon
Margin of safety -676.2% vs hist-growth DCF
Historical 3Y CAGR
-10.4%
Your model implies
14.0%
Analyst consensus is EPS-only — no comparable FCF / share estimate to show on this basis.
Model inputs
Move sliders to test how the reverse DCF reacts. Historical-growth markers show where the company has actually grown over the last cycle.
Undiscounted FCF per share over 10 years at -10% annual growth.
Sensitivity — implied growth vs your assumptions
Each cell shows the per-share growth rate the market would need to justify the current price at that combination of discount rate (rows) and terminal growth (columns). Your selected inputs are highlighted.
| Row axis: discount rate. Column axis: terminal growth.Terminal g →↓ Discount | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.0% | 13.6% | 12.1% | 10.2% | 8.0% | 5.1% |
| 5.0% | 13.6% | 12.1% | 10.2% | 8.0% | 5.1% |
| 5.8% | 16.7% | 15.5% | 14.0% | 12.4% | 10.4% |
| 6.8% | 19.9% | 18.9% | 17.7% | 16.5% | 15.0% |
| 7.9% | 22.7% | 21.8% | 20.9% | 19.9% | 18.7% |
Historical multiples
Each bar is the trailing five-year range (low left, high right). Filled portion runs from low to today; the dot marks today; the small tick marks the five-year median. Low, median, and high are listed under each bar.
Net cash
$412M
Total debt − cash
Beta
0.24
Vs market benchmark
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.